RBC Initiates AbbVie Coverage with Outperform Rating, Highlights Growth Potential
RBC Capital Markets has launched coverage of AbbVie (ABBV) with an outperform rating and a $260 price target, suggesting a 14% upside from current levels. Analyst Trung Huynh dismisses bearish concerns, emphasizing Skyrizi and Rinvoq as key growth drivers still in their early stages of market expansion.
The firm notes AbbVie's lack of near-term patent cliffs—a critical advantage in the pharmaceutical sector—and its avoidance of dependency on mergers and acquisitions for growth. Trading at under 16x earnings, AbbVie's valuation aligns more closely with traditional pharma peers rather than high-growth biotech names.
Separately, AbbVie announced a $380 million investment to establish two new API manufacturing facilities in North Chicago, expected to create 300 jobs. This strategic MOVE underscores the company's commitment to scaling production capacity amid rising demand for its flagship therapies.
